CMC(SH:603122) 财联社·2025-11-14 12:31Core Viewpoint - The stock of HeFu China has surged over 256.29% in a short period, leading to a suspension for verification due to abnormal trading activities and potential irrational speculation [1][4]. Group 1: Stock Performance and Trading Activities - HeFu China announced that from October 28 to November 14, 2025, its stock experienced 12 out of 14 trading days closing at the limit-up price, with a total increase of 256.29% [1]. - The stock's trading volume showed significant fluctuations, with a turnover rate reaching 28.48% on November 14, indicating a "hot potato" effect in the market [1][2]. - The company has warned investors about the risks associated with the rapid price increase and the potential for a quick decline [1]. Group 2: Company Fundamentals and Financial Performance - HeFu China's main business involves international trade and after-sales services related to in vitro diagnostic medical devices and consumables [4]. - According to the third-quarter report for 2025, the company reported a net loss of 5.048 million yuan, a decline of 225.26% compared to the same period last year, primarily due to changes in domestic macroeconomic conditions and price reductions from centralized procurement policies [4].